Recovery & Repair · Compounded 503A · Subcutaneous or oral
BPC-157: the gut-derived peptide built for systemic repair.
BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. It is the most studied off-label peptide in orthopedic and gut repair — driving angiogenesis, modulating the nitric oxide pathway, and accelerating tendon and ligament healing in extensive animal data.
Free shipping over $150 · Pay with card or crypto
What BPC-157 is
BPC-157 (Body Protective Compound-157) is a partial sequence of a protective protein isolated from human gastric juice. The synthetic 15-amino-acid peptide was characterized by Sikiric and colleagues at the University of Zagreb beginning in the early 1990s.
It is the most extensively studied peptide in the orthopedic and gastrointestinal repair literature — with hundreds of animal studies covering tendon, ligament, muscle, bone, intestinal, and CNS injury models.
BPC-157 is not FDA-approved and is compounded by licensed 503A pharmacies for prescription off-label use. It is commonly paired with TB-500 in clinical recovery protocols.
How it works
BPC-157 promotes angiogenesis — the formation of new blood vessels — by upregulating VEGFR2 and modulating the nitric oxide (NO) pathway. Better vasculature at the injury site is a prerequisite for accelerated repair.
It increases expression of the growth-hormone receptor on tenocytes and fibroblasts, sensitizing connective tissue to circulating GH. Tendon strength and rate of repair improve in standardized transection models.
In the gut, BPC-157 protects mucosal integrity, accelerates ulcer healing, and modulates the gut-brain axis. It is unusually stable to gastric acid, allowing meaningful oral bioavailability — uncommon for peptides.
What patients use it for
Tendon and ligament repair
Strongest signal in the literature. Standardized rat Achilles transection models show faster reconnection, organized collagen, and superior tensile strength versus controls.
Gastrointestinal protection and repair
Accelerates gastric, duodenal, and colonic ulcer healing. Studied in NSAID-induced and stress-induced injury, IBD models, and short-bowel syndrome.
Pairs with TB-500
Mechanisms are complementary — BPC-157 drives angiogenesis and growth-factor signaling; TB-500 drives cell migration via actin binding. The combination is the most common orthopedic stack.
Anti-inflammatory and neuroprotective signal
Animal evidence in TBI, stroke, and peripheral nerve injury — early-stage and not yet validated in humans.
Evidence summary
Sikiric P et al. (Curr Pharm Des 2010, 2018) review summarizes the broad BPC-157 evidence base across GI, musculoskeletal, and CNS injury models.
Chang CH et al. (J Orthop Res 2011): BPC-157 accelerated tendon-to-bone healing and improved tensile strength in a rat Achilles model.
Human trial data are sparse. Most clinical use rests on extensive animal mechanism work plus real-world dosing experience in U.S. compounding pharmacies and international clinics. Honest framing requires acknowledging this evidence gap.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Common protocols: 250–500 mcg subcutaneously once or twice daily for 4–6 weeks, often near the site of injury when anatomically reasonable.
Oral BPC-157: 250–500 mcg once or twice daily for GI indications; oral form is preferred when targeting gut mucosa.
Frequently paired with TB-500 (2–5 mg twice weekly) for orthopedic indications. Course length individualized to injury severity and rehab progress.
Safety and contraindications
Very well tolerated in clinical experience. Most common report is mild injection-site reaction.
No reproductive, developmental, or long-term human safety data — avoid in pregnancy, breastfeeding, and active malignancy.
Compounded BPC-157 is not FDA-approved and is restricted to physician-supervised off-label use through a licensed 503A pharmacy.
WADA prohibits BPC-157 in competitive sport. Tested athletes should not use without consulting their governing body.
Who it's typically considered for
- Adults with slow-healing tendon, ligament, or muscle injuries (after orthopedic evaluation)
- Patients with NSAID gastropathy, post-surgical gut healing, or IBD flares (under GI guidance)
- Athletes in post-injury rehabilitation (non-tested populations)
- Patients already using or considering TB-500
Frequently asked questions
Is BPC-157 legal in the U.S.?
BPC-157 is not FDA-approved and is not legally sold over the counter as a drug. It can be prescribed off-label and compounded by a licensed 503A pharmacy. Internet "research-use" sources are not legal for human use.
BPC-157 vs TB-500 — which should I use?
Many clinicians use both. BPC-157 drives angiogenesis and GH-receptor expression; TB-500 drives cell migration via actin binding. The combination outperforms either alone for orthopedic injury in clinical experience.
How quickly does it work?
Most patients report progress within 2–4 weeks. Tendon and ligament tissue remodels over months — visible function gains usually arrive faster than complete structural repair.
Oral vs injection — which is better?
For systemic or musculoskeletal use, subcutaneous injection is the preferred route. For gut-targeted use (gastritis, IBD adjunct), oral has the advantage of local mucosal exposure.
Is BPC-157 safe for cancer survivors?
BPC-157's pro-angiogenic activity is mechanistically concerning in active cancer. In survivors without active disease, use should be coordinated with the patient's oncologist.
Can women use BPC-157?
Yes — there is no sex-specific contraindication. Avoid in pregnancy and breastfeeding due to lack of human data.
Will it show up on a drug test?
Standard clinical drug screens do not detect BPC-157. Specialized anti-doping panels can detect it; WADA prohibits it in competitive sport.
Is BPC-157 the same as PEA or other repair peptides?
No. PEA (palmitoylethanolamide) is a lipid mediator, not a peptide. KPV, LL-37, and thymosin alpha-1 are other repair-adjacent peptides with distinct mechanisms.
Sources
- Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — A Comprehensive Review. Curr Pharm Des (2018). — pubmed.ncbi.nlm.nih.gov/29874990
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011). — pubmed.ncbi.nlm.nih.gov/21127170
- Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res (2006). — pubmed.ncbi.nlm.nih.gov/16435362
- Seiwerth S et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des (2018). — pubmed.ncbi.nlm.nih.gov/29945508
Considering BPC-157?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.